학술논문
Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
Document Type
Clinical report
Author
Quiroga, Borja; Soler, Maria Jose; Ortiz, Alberto; Mantecon, Carlos Jesus Jaravaca; Perez, Nathasha Nava; Martin, Marta Serra; Sato, Yurika; Franco, Antonio Jose Marin; Zambrano, Diana Flor Pazmino; Valverde, Rafael Lucena; Diaz, Mayra Ortega; Gonzalez, Carmen Calderon; Lopez, Juan Manuel Cazorla; Pereira, Monica; Parra, Emilio Gonzalez; Horrillo, Ana Sanchez; Gonzalez, Carmen Sanchez; Toapanta, Nestor; Guldris, Secundino Cigarran; Hernandez, Rosa Sanchez; Sanchez, Soledad Pizarro; Rincon, Maria Muniz; Garcia-Fernandez, Nuria; Castro, Natalia Blanco; Mateo, Rocio Collantes; Morales, Manuel Augusto Quiroz; Escamilla-Cabrera, Beatriz; Godoy, Isabel Berdud; Casanova, Beatriz Gil-Casares; Leyva, Alba; Rojas, Jose; Gansevoort, Ron T.; Sequera, Patricia de
Source
Clinical Kidney Journal. October, 2022, Vol. 15 Issue 10, p1856, 9 p.
Subject
Language
English
ISSN
2048-8505
Abstract
Background. Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods. This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results. A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001). Conclusions. In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection. Keywords: booster, COVID-19, hemodialysis, SARS-CoV-2, vaccination
INTRODUCTION Patients undergoing hemodialysis present higher mortality secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. SARS-CoV-2 vaccines attenuate the risk of complications such as severe coronavirus disease [...]
INTRODUCTION Patients undergoing hemodialysis present higher mortality secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. SARS-CoV-2 vaccines attenuate the risk of complications such as severe coronavirus disease [...]